Echocardiographic Findings in Stable Outpatients with Properly Functioning HeartMate II Left Ventricular Assist Devices




Background


Continuous-flow left ventricular assist devices (LVADs) have become part of the standard of care for the treatment of advanced heart failure. However, knowledge of normal values for transthoracic echocardiographic examination and measurements in these patients are lacking.


Methods


All transthoracic echocardiographic examinations in 63 consecutive patients, performed 90 and 180 days after surgery with the implantation of a HeartMate II continuous-flow LVAD between February 2007 and January 2010, were retrospectively analyzed. All patients had to be outpatients at 3 and 6 months after surgery and considered stable on LVAD therapy (New York Heart Association class I or II and no need for inotropes, intravenous furosemide, or hospitalization).


Results


End-diastolic and end-systolic diameters and left ventricular mass decreased considerably compared with baseline measurements before LVAD implantation. Mitral inflow deceleration time increased (188 ± 70 vs 132.5 ± 27 msec, P = .009) and left atrial volume (84.1 ± 33 vs 141.7 ± 62 mL, P = .003) and E/e′ ratio decreased (20.3 ± 9 vs 26 ± 11, P = .01), all consistent with decreased left ventricular filling pressure. Estimated right ventricular (RV) and right atrial pressure decreased significantly (34.1 ± 10 vs 51.7 ± 14 mm Hg and 9.5 ± 5 vs 14.4 ± 5 mm Hg, respectively, P < .0001 for both). Quantitatively estimated RV function ( P = .02), RV fractional area change (27.9 ± 10% vs 37.4 ± 10.9%, P < .0001), and the RV index of myocardial performance (0.32 ± 0.1 vs 0.65 ± 0.2 vs 0.32 ± .01, P < .0001) improved, suggesting improved RV efficiency. LVAD therapy resulted in significant decreases in the severity of mitral regurgitation. Tricuspid regurgitation improved in patients who had concurrent tricuspid surgical correction and was unchanged otherwise. Aortic regurgitation severity increased 3 months after LVAD implantation. There were no significant differences in any of the echocardiographic parameters in the 6-month evaluation compared with the 3-month evaluation.


Conclusions


This is the first report of selected typical echocardiographic values in a group of stable patients with normally functioning HeartMate II continuous-flow LVADs. A stable functioning continuous LVAD is associated with evidence of efficient unloading of the left ventricle, improved RV function, significant improvement in mitral regurgitation, improvement in tricuspid regurgitation only in patients undergoing repair, and increased aortic regurgitation. These normal data provide a basis for future echocardiographic studies after LVAD implantation.


Left ventricular (LV) assist devices (LVADs) are designed for mechanical support for patients with severe systolic heart failure. LVAD therapy provides effective long-term circulatory support as a bridge to transplantation or as destination therapy. In most cases, axial flow pumps have replaced pulsatile LVADs because they have been shown to have improved survival and have less device failure. Recently, the HeartMate II continuous-flow assist device (Thoratec Corporation, Pleasanton, CA) was approved for use as a bridge to transplantation or as destination therapy by the US Food and Drug Administration.


Preoperative and postoperative transthoracic echocardiography has a major role in the management of patients with LVADs. Transthoracic echocardiography is frequently used to assist in patient selection for LVAD therapy, evaluation of proper native heart and LVAD function, and troubleshooting for possible device malfunctions. Although continuous LVAD therapy has been in clinical use for a number of years, a comprehensive summary of normal values for the different echocardiographic measurements in these patients has not been reported to date. We report here for the first time echocardiographic parameters, including LV linear dimensions, chamber areas, valvular function, and Doppler evaluation, obtained from a large patient population having undergone successful LVAD implantation with HeartMate II devices, with improved functional outcomes (New York Heart Association [NYHA] class I or II and no need for inotropes, intravenous furosemide, or hospitalization) at 3 and 6 months after LVAD implantation. We also report the influence of a properly functioning LVAD system on the appearance and function of the different chambers, walls, and valves of the native heart.


Methods


Patient Population


We retrospectively analyzed data from 63 consecutive patients (52 men, 11 women) who had been supported for ≥90 days with continuous-flow HeartMate II LVADs between February 2007 and January 2010. All subjects were in NYHA functional class I or II at follow-up, with no echocardiographic or clinical evidence of device malfunction, no need for intravenous inotropic support or diuretics, and no other significant illness requiring hospitalization at the time of baseline (90 days after LVAD surgery) or 6-month echocardiographic examination. All 63 patients underwent comprehensive echocardiographic examinations preoperatively and at 90 days after LVAD surgery. Thirty-nine patients underwent follow-up echocardiographic examinations 180 days after surgery.


Echocardiographic Measurements


Two-dimensional transthoracic echocardiography was performed in a standard manner using the Sonos 5500 (Philips Medical Systems, Andover, MA), Sequoia 512 (Siemens Medical Solutions USA, Inc., Mountain View, CA), or Vivid 7 (GE Medical Systems, Milwaukee, WI).


LV diameters and interventricular septal and posterior wall width were measured from the parasternal short-axis view using two-dimensional or two-dimensionally guided M-mode echocardiography of the left ventricle at the papillary muscle level using the parasternal short-axis view from the trailing edge of the septum to the leading edge of the posterior wall, as recommended. Ejection fraction was calculated using the Quinones method, assuming an akinetic apex, and LV mass was calculated using the method proposed by Devereux et al. , using the same LV dimensions made with M-mode or two-dimensional echocardiography as described above.


Valvular regurgitation was qualitatively assessed using color Doppler according to the guidelines of the American Society of Echocardiography (normal or trivial = 1, mild = 2, moderate = 3, and severe = 4). Right ventricular (RV) chamber size and function were measured according to the guidelines of the American Society of Echocardiography. RV size and systolic function were evaluated by measuring RV end-diastolic area (four-chamber view), RV end-systolic area (four-chamber view), and tricuspid annular end-systolic diameter (four-chamber view) and calculating RV fractional area change. RV function was qualitatively graded using a four-point grading system (normal, mild, moderate, or severe) using all apical views and the RV inflow, parasternal long-axis, parasternal short-axis, and subcostal views. Care was taken to obtain a true, nonforeshortened apical or para-apical four-chamber view, oriented to obtain the maximum RV dimension before making the RV estimation. RV function was then assessed using two other methods: two-dimensional lateral tricuspid annular motion and the RV index of myocardial performance (RIMP), as previously described by others ( Figures 1 and 2 , Videos 1 and 2 ; view video clips online). Tricuspid annular diameter was measured at end-systole as well. The RV outflow tract (RVOT) velocity-time integral (VTI) was measured from pulsed-wave Doppler, and RVOT diameter was measured from the parasternal short-axis view at the level of the great arteries. Total RV output (the sum of LVAD output and the flow ejected through the LV outflow tract) was calculated using the formula (RV outflow diameter/2) 2 × π × RV outflow VTI. Mean pulmonary artery pressure was estimated using the modified Bernoulli formula: [4 × (peak systolic tricuspid regurgitation [TR] velocity at end-expiration) 2 ] + right atrial pressure estimated by the inferior vena cava diameter as well as its response to inspiration, as previously described. Measurements of the LVAD components were performed, including the inflow cannula, outflow graft flow velocities, and native aortic valve opening status ( Figures 3–5 ).




Figure 1


(A) Parasternal long-axis view showing severely dilated left ventricle (end-diastolic dimension, 85 mm). (B) Apical four-chamber view showing a short E-wave deceleration time, suggesting very high LV end-diastolic pressure. (C) RV ejection time was measured from pulsed-wave Doppler of the RVOT flow, and tricuspid valve flow time was measured from the interval between the onset and cessation of TR flow using continuous-wave Doppler echocardiography. RIMP was calculated as (TR flow time − RV ejection time)/RV ejection time. Note the very short RV ejection time, suggesting low RV output, and the TR signal, suggesting prolonged positive and negative dP/dt. The calculated RIMP is increased, suggesting that the right ventricle is spending most of the time in isovolumic contraction and relaxation and not in ejection (inefficiency). (D) End-diastolic diameter decreased and the septal and posterior walls thickened. (E) E-wave deceleration time lengthened, suggesting a decrease in LV end-diastolic pressure. Note also the plateau in mid-diastolic flow velocity resulting from the continuous suction created by the LVAD throughout diastole. (F) RV ejection time is longer, suggesting improved RV output. TR flow time is shorter and RIMP is smaller, suggesting improved RV efficiency (more time in ejection and less time spent as isovolumic contraction and relaxation). Note that the TR signal is symmetric and steeper, suggesting improved positive and negative dP/dt.



Figure 2


(A) Right ventricular end-diastolic area (RVEDA) and (B) right ventricular end-systolic area (RVESA) were traced before LVAD therapy (see Video 1 ). Right ventricular fractional area change (RVFAC) was calculated as (RVEDA − RVESA)/RVEDA. (C,D) RVEDA and (B) RVESA were traced 3 months after LVAD implantation (see Video 2 ). (C) RVEDA was unchanged, RVESA decreased, and calculated RVFAC improved after LVAD implantation. LA , Left atrium; LV , left ventricle; RA , right atrium.



Figure 3


(A) Interrogation of the inflow cannula (see Video 3 ). Inflow cannula and its orientation within the left ventricular apex visualized on the apical four-chamber view, aligned with the left ventricular inflow tract, not touching any wall. Note the properly aligned inflow cannula with laminar and unidirectional flow from the left ventricle (LV) to the device (red). (B) Pulsed-wave Doppler assessment showing laminar, low-velocity forward flow without regurgitation with a pulsatile inflow pattern because the pump inflow originates from the beating LV, resulting in periodic changes in flow throughout the cardiac cycle, reaching a maximum during systole and a minimum during diastole. Maximal systolic and diastolic velocities were recorded, and the difference between them was calculated. The difference between systolic and diastolic inflow velocities is related to left ventricular contraction in a geometry-independent way. (C) Interrogation of the outflow cannula (OC) in the high left parasternal long-axis view showing the end-to-side anastomosis of the OC to the mid ascending aorta (see Video 4 ). (D) Interrogation of the OC in the low right parasternal view (positioned in the sixth to seventh intercostal space) so that the color Doppler shows the typical continuous color flow pattern toward the transducer (red) coming from the pump toward the proximal OC (see Video 5 ). (E) We then continue to follow the OC along the right side of the sternum as it transverses upward toward the ascending aorta (see Video 6 ). In the midsternum, the cannula is parallel to the transducer, and the color flow transforms from red to blue. (G) We continue to follow the OC to the high parasternal area (see Video 7 ). The flow will change direction away from the transducer (blue), bending toward the ascending aorta. This is usually the best view to measure flow velocity, with the pulsed-wave sample (the angle of interrogation will be optimal) positioned ≥1 cm proximal to the aortic anastomosis and the flow moving away from the transducer. AO , Aorta; Asc , ascending; RA , right atrium; RPA , right pulmonary artery; RV , right ventricle.



Figure 4


Pulsed-wave Doppler of the outflow cannula (1) and M-mode echocardiography of the aortic valve (2) in three patients (A–C) with normal LVAD function. The status of aortic valve opening and aortic flow pulsatility depend on pump speed and output, LV contractility, preload, and afterload conditions. Reduction in LVAD speed with reduced unloading of the left ventricle or increased native LV contractility will increase LV systolic pressure above aortic pressure allowing pulsatile flow (A1) and aortic valve opening during every cycle (A2) . Increasing the speed to further unload the ventricle or reduced native heart contraction will result in reduced systolic LV pressure, decreased outflow pulsatility (B1) , and intermittent aortic valve opening (B2) . Increasing speed to maximum and further unloading of the left ventricle or markedly decreased native heart contractility will result in nearly continuous LVAD aortic flow (C1) and a permanently closed aortic valve (C2) .



Figure 5


Although pump flow can be estimated by the device controller, we prefer to measure it directly during the echocardiographic examination. (A) First, we measure the outflow cannula diameter in the right parasternal view, calculating its surface area. (B) Second, we measure the outflow cannula flow integral by pulsed-wave Doppler 1 cm proximal to its anastomosis to the aorta. This can be done in the low right parasternal view (flow toward the transducer), high right parasternal view (flow away from the transducer), or high left parasternal view (flow away from the transducer). We usually measure the integral of flow of three successive cycles and divide the number by 3 to receive the flow for one cycle. We then calculate the pump flow using the equation LVAD output = (cannula diameter/2) 2 × π × cannula flow time-velocity integral (TVI) × heart rate (HR). (C) For total cardiac output estimation, we measure the RVOT diameter in the short-axis view on the level of large vessels and calculate its surface area. (D) Second, we measure the RVOT flow integral by pulsed-wave Doppler in the same view. We then calculate the total cardiac output by multiplying these measurements by the heart rate.


Inflow Cannula


The inflow cannula and its orientation within the LV apex were visualized in the apical four-chamber and two-chamber views and sometimes required off-axis imaging as well. Doppler assessment of the inflow cannula was done in the four-chamber and two-chamber views as well, because they are usually aligned with the central axis of a properly positioned inflow cannula. Continuous-wave Doppler was used for measurement of the maximal velocity along the inflow pathway from the ventricle to the LVAD. Maximal systolic and diastolic velocities were recorded using pulsed-wave Doppler or continuous-wave Doppler, and the ratio of systolic to diastolic inflow velocities was calculated ( Figure 3 , Video 3 ; view video clip online).


Outflow Cannula


Interrogation of the outflow cannula was performed from the high left parasternal long-axis view, which shows the end-to-side anastomosis of the outflow cannula to the mid ascending aorta, and the right parasternal view, which shows the long axis of the outflow cannula traversing from the pump toward the right aspect of the ascending aorta. Color flow, pulsed-wave, and continuous-wave Doppler were used to evaluate flow patterns of the outflow cannula. To measure flow velocity, the pulsed-wave sample volume was positioned ≥1 cm proximal to the aortic anastomosis, and the flow was recorded away from or toward the transducer, depending on the transducer position. For the right parasternal view, the patient was positioned on his or her right side, and the image was recorded with the transducer immediately rightward to the sternum ( Figure 3 , Videos 4–7 ; view video clips online).


The product of a pulsed-wave spectral Doppler VTI from the outflow cannula and its cross-sectional area equals the flow volume created by the pump. This technique is well known and was recently validated with the HeartMate II in a well-conducted in vitro study. The same method was applied here to calculate the LVAD minute flow rate ( Figure 5 ). LVAD outflow cannula diameter was measured in the right parasternal view, and outflow VTI was measured using the right parasternal view or the high left parasternal view, depending on which view afforded the lowest Doppler angle of interrogation. In some patients, the outflow cannula diameter could not be measured because of variations in imaging plane. We examined whether the pump’s flow volume could be estimated using a simplified method using the product of a pulsed-wave spectral Doppler VTI from the outflow cannula and an outflow cross-sectional area calculated assuming a diameter of 16 mm (which is the actual manufactured measurement) or any other constant.


LVAD Settings


We routinely use an echocardiographically guided “ramped speed study” to set the optimal pump speed before discharge. We generally use a fixed speed setting that falls midway between the minimum and maximum speeds on the basis of the surgeon’s preference and changes in ventricular dimensions, the position of the interatrial septum and interventricular septum, and the frequency of aortic valve opening ( Figure 4 ).


Tricuspid Repair and Replacement


Candidates for LVAD implantation are evaluated using echocardiography to assess native TR. Those with at least moderate TR (jet area/right atrial area ≥20% or vena contracta >4.5 mm) need to undergo tricuspid valve repair or replacement. For tricuspid valve repair, the valve was inspected for pathology. If TR was associated with annular dilatation, a flexible annuloplasty ring (either complete or incomplete) was implanted to tighten the tricuspid annulus. If TR was related to entrapped leaflets from defibrillator or pacemaker leads, the responsible portion of the leads was freed from the leaflets and tucked into the commissure between the septal and posterior leaflets within a modified Kay annuloplasty stitch. If uncorrectable TR pathology was noted (too many adhesions, significant valvular tenting, severe TR such that repair was not likely to hold), we proceeded with tricuspid valve replacement using a tissue valve.


Aortic Valve Stitch


Candidates for LVAD implantation were evaluated using echocardiography to assess for native aortic valve insufficiency. Those with aortic insufficiency due to significant structural defects in the aortic valve underwent aortic valve replacement or patch closure of the valve. However, the majority of patients with aortic insufficiency were corrected with a simple coaptation stitch placed at the central portion of the aortic cusps, as previously described. The ascending aorta was cross-clamped to arrest the heart. A lateral aortotomy incision was made, long enough to complete the anastomosis between the outflow graft and the aorta. An aortic root retractor was placed, and the native aortic valve was inspected through the incision. The cusps of the native aortic valve were carefully examined to make sure that no other structural problems could be causing the aortic insufficiency. If the central aortic insufficiency was due to poor coaptation, a simple coaptation stitch using pledget-supported 5-0 Prolene sutures at the center easily mended this problem. Using this approach, the aortic valve was still able to open for ejection, even though the effective orifice area of the aortic valve was diminished. After placement of the coaptation stitch, the anastomosis between the outflow graft and the aorta was completed in the usual fashion.


Interobserver and Intraobserver Variability


Interobserver variability was assessed by comparing the readings made by another independent echocardiographer in 15 randomly selected patients. Intraobserver variability was determined by having the first observer who measured the data in all patients remeasure the velocities in 15 patients ≥3 month apart. The degrees of interobserver and intraobserver variability were determined using the Bland-Altman method and the within-subjects coefficient of variation. The within-subjects coefficient of variation (calculated as ratio of the standard deviation of the measurement difference to the mean value of all measurements) provides a scale-free, unitless estimate of variation expressed as a percentage. We measured the intraobserver and interobserver reproducibility for the inflow cannula velocity, the outflow cannula velocity, and the outflow cannula VTI, and the variations in measurements were expressed as ratios.


Statistical Analysis


Data are presented as mean ± SD, as percentages, or as medians with first and third quartiles, as appropriate. Comparisons between patients before and after LVAD implantation were performed using the paired Student’s t test or Wilcoxon’s signed-rank test, as appropriate. To analyze potential factors that influence the progression in aortic regurgitation (AR) (dichotomized into worse or stable AR by comparing AR grade at the baseline, 3 month and 6 month evaluations), univariate analyses on the basis of logistic regression were performed on various parameters (clinical, hemodynamic, and echocardiographic). All P values were two sided, and values < .05 were considered statistically significant. All data were analyzed using JMP version 8.0 (SAS Institute Inc., Cary, NC).




Results


The demographic, clinical, and hemodynamic characteristics of all patients are listed in Table 1 . Most patients were men aged >60 years with ischemic cardiomyopathy. All patients had NYHA class IIIB or IV symptoms, with hemodynamic parameters consistent with severe heart failure, a mean LV ejection fraction of 19.4 ± 7.2%, mean peak oxygen consumption of 10.6 ± 2.2 mL/kg/min, and a mean cardiac index of 1.9 ± 0.5 L/min/m 2 .



Table 1

Baseline characteristics of all patients before LVAD implantation



























































































Characteristic Value
Clinical, surgical, and demographic
Age (y) 63.8 ± 13.0
Men 82.5%
Previous sternotomy 47.6%
TV repair/replacement 38.1%
Aortic repair (Park’s stitch) 7.9%
NYHA class IV 52.4%
Destination 61.9%
Ischemic 53.9%
Presence of LBBB 10.8%
Hemodynamic variables
Heart rate (beats/min) 77.6 ± 15.6
Systolic blood pressure (mm Hg) 98.1 ± 11.5
Diastolic blood pressure (mm Hg) 63.3 ± 8.1
Mean RA pressure (mm Hg) 14.9 ± 6.5
Mean PA pressure (mm Hg) 36.6 ± 9.6
RV dP/dt 471.1 ± 213.1
Mean wedge pressure (mm Hg) 23.7 ± 6.5
Cardiac index (L/min/m 2 ) 1.8 ± 0.5
SVR (Wood units) 18.3 ± 8.4
Hemoglobin (g/dL) 12.2 ± 1.9
Platelet count (×10 3 /μL) 170.8 ± 69.6
INR 1.5 ± 0.7
Bilirubin (mg/dL) 1.2 ± 0.7
Albumin (g/dL) 3.7 ± 0.5
BUN (mg/dL) 31.8 ± 16.4
Creatinine (mg/dL) 1.5 ± 0.5
BNP (pg/mL) 1,901 ± 1,619

Data are expressed as mean ± SD or as percentages.

BNP , Brain natriuretic peptide; BUN , blood urea nitrogen; INR , international normalized ratio; LBBB , left bundle branch block; PA , pulmonary artery; RA , right atrial; SVR , systemic vascular resistance; TV , tricuspid valve.

Performed during the index LVAD surgery.



Linear LV dimensions, chamber function, valvular function, and Doppler evaluation obtained from patients at preoperative baseline and at 3 months after LVAD surgery are presented in Table 2 . LV dimensions changed significantly with continuous LVAD support. LV end-diastolic and end-systolic diameters decreased considerably (−15.8 ± 12.9% and −20.8 ± 18.8%, respectively, P < .0001). Septal wall and posterior wall thickness increased, but the difference did not reach statistical significance ( Table 2 , Figure 1 ). The calculated LV mass decreased (−19.4 ± 25.2%, P < .0001), and the mean LV ejection fraction improved (19.4 ± 7.2% vs 26.2 ± 12.4%, P < .0001).



Table 2

Echocardiographic parameters before and 3 and 6 months after LVAD implantation




















































































































































































































































Variable Before LVAD implantation 3 months after LVAD implantation P 6 months after LVAD implantation
LV parameters
LV diastolic diameter (mm) 68.3 ± 9.1 56.7 ± 11.4 <.0001 57.4 ± 12.6
LV systolic diameter (mm) 61.7 ± 9.0 47.8 ± 13.0 <.0001 49.0 ± 13.9
Posterior wall thickness (mm) 10.0 ± 1.8 10.1 ± 2.0 .46 10.6 ± 1.5
Interventricular septal wall thickness (mm) 10.3 ± 2.1 10.8 ± 3.3 .15 10.8 ± 2.1
Ejection fraction (%) 19.4 ± 7.2 26.2 ± 12.4 .0004 27.7 ± 14.7
LV mass (g) 383.6 ± 113.8 295.9 ± 118.9 <.0001 314.8 ± 134.4
Diastolic parameters
LA volume index (mL/m 2 ) 69.3 ± 30.0 42.5 ± 15.9 .009
E-wave velocity (m/sec) 0.98 ± 0.35 1.0 ± 1.6 .9 0.8 ± 0.2
E-wave deceleration time (msec) 132.5 ± 27.0 188.0 ± 70.1 .009 166.3 ± 48.4
Tissue Doppler e′ (septal wall) 0.04 ± 0.01 0.04 ± 0.01 .9
E/e′ ratio 26.0 ± 11.5 20.3 ± 9.5 .01 13.9 ± 7.9
RV parameters
RV end-diastolic area (cm 2 ) 32.0 ± 8.6 29.3 ± 6.4 .0002
RV end-systolic area (cm 2 ) 23.2 ± 7.2 18.6 ± 5.6 <.0001
RV fractional area change (%) 27.9 ± 10 37.4 ± 10.9 <.0001
Tricuspid annular systolic diameter (cm) 3.6 ± 0.6 3.3 ± 0.5 <.0001
Estimated RA pressure (mm Hg) 14.4 ± 5.1 9.5 ± 5.1 <.0001 8.6 ± 4.9
Estimated pulmonary pressure (mm Hg) 51.7 ± 14.3 34.1 ± 10.2 <.0001 33.5 ± 10.6
RIMP 0.65 ± 0.23 0.32 ± 0.16 <.0001 0.44 ± 0.27
TV lateral annular velocity (m/sec) 0.08 ± 0.02 0.08 ± 0.03 .4 0.07 ± 0.01
RV functional grade 3 (2.5–4) 3 (2–3.5) .02
Valvular parameters
AR grade 0 (0–0) 0 (0–1) .004 1 (1–1)
AR VC (mm) 0.38 ± 0.9 2.0 ± 1.6 <.0001 1.7 ± 0.9
MR grade 2 (0–4) 0 (0–1) <.0001 0 (0–1)
MR VC (mm) 3.1 ± 2.4 2.1 ± 1.9 .04
TR grade 2 (0.5–4) 1 (0–2) <.0001 1.5 (1–2)
TR VC (mm) 3.8 ± 2.5 2.6 ± 1.7 .001
PR grade 0 (0–1) 0 (0–0) .003 1 (0–1)
LVAD parameters
Inflow cannula velocity systolic (cm/sec) 76.2 ± 37.2
Inflow cannula velocity diastolic (cm/sec) 24.6 ± 13.5
LVAD inflow systolic to diastolic ratio 3.4 ± 1.9
Outflow cannula velocity (cm/sec) 104.7 ± 37.1
Outflow cannula VTI (cm) 40.7 ± 11.1
Calculated total output (L/min) 5.8 ± 1.6
Calculated LVAD output (L/min) 5.1 ± 1.2

Data are expressed as mean ± SD or as median (interquartile range).

LA , Left atrial; PR , pulmonary regurgitation; RA , right atrial; TV , tricuspid valve; VC , vena contracta.

Before versus 3 months after LVAD implantation.


Graded visually as described in the “Methods” section.


Measured in the 50 patients with nonforeshortened four-chamber views.



Evaluation of indices of LV filling pressure showed significant prolongation of mitral inflow deceleration time of E-wave velocity, significant decrease in left atrial volume index, and a significant decrease in E/e′ ratio ( Table 2 ), all supportive of decreased LV filling pressure at 3 months after LVAD implantation. Interestingly, in those with left bundle branch block, the E/e′ ratio did not decrease and even increased slightly (5 ± 3% vs −38 ± 10%, P = .005).


The calculated RV pressure decreased significantly (−30.7 ± 26.2%, P < .0001), as did the estimated right atrial pressure ( Table 2 ). The quantitative estimation of RV function improved, RV end-diastolic and end-systolic areas decreased (32.0 ± 8.6 vs 29.3 ± 6.4 cm 2 , P = .0002, and 23.2 ± 7.2 vs 18.6 ± 5.6 cm 2 , P < .0001, respectively), RV fractional area change improved (27.9 ± 10% vs 37.4 ± 10.9%, P < .0001), and RIMP decreased significantly (0.69 ± 0.28 vs 0.34 ± 0.19, P < .0001) with LVAD therapy, suggesting improved RV function ( Figures 1 and 2 ). Interestingly, longitudinal contraction (lateral tricuspid annular motion velocity) did not change after LVAD implantation ( Table 2 ).


Follow-up measurements were available in 39 patients at 6 months after LVAD implantation ( Table 2 ). There were no significant differences in any of the echocardiographic variables compared with the measurements obtained at 3 months.


We assessed the effect of LVAD support on the severity of valvular regurgitation. LVAD therapy resulted in a significant decrease in the severity of mitral regurgitation (MR).


A common practice at the time of LVAD implantation consists of tricuspid valve repair or replacement, whenever TR is more than moderate. To better understand the effect of these interventions on regurgitation severity, we separated the patients into those who underwent or did not undergo tricuspid intervention during the initial LVAD surgery. TR severity improved significantly in patients in whom tricuspid valve intervention was performed but was unchanged in those without any tricuspid valve intervention ( Table 3 ). Our data show that TR did not improve in patients in whom the interventricular septum was deviated to the left ( Table 3 ).



Table 3

Comparison of the severity of TR and AR after LVAD surgery depending on the use of concomitant tricuspid surgery, aortic surgery, septal position, or rate of aortic valve opening














































Before implantation After implantation Before implantation After implantation Before implantation After implantation Before implantation After implantation
No TR surgery ( n = 40) TR surgery ( n = 23) IVS to left ( n = 5) IVS to right ( n = 58)
TR VC (mm) 2.8 ± 2.0 (NS) 2.5 ± 1.6 (NS) 5.5 ± 2.3 2.6 ± 1.9 4.7 ± 2.6 (NS) 4.7 ± 1.9 (NS) 3.7 ± 2.5 2.4 ± 1.6
No AR stitch ( n = 58) AR stitch ( n = 5) Aortic valve opening ( n = 23) Aortic valve closed ( n = 40)
AR VC (mm) 0.34 ± 0.82 2.0 ± 1.6 2.3 ± 1.8 (NS) 1.2 ± 0.9 (NS) 0.33 ± 0.6 1.7 ± 1.4 0.6 ± 1.2 2.1 ± 1.6

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jun 15, 2018 | Posted by in CARDIOLOGY | Comments Off on Echocardiographic Findings in Stable Outpatients with Properly Functioning HeartMate II Left Ventricular Assist Devices

Full access? Get Clinical Tree

Get Clinical Tree app for offline access